Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Lenalidomide (LEN) in INT 2 and High Risk MDS with DEL 5q. Interim Results of a Phase II Trial by the GFM.

S. Burcheri, MD, T. Prebet, MD, O. Beyne-Rauzy, MD, R.M. Mbida, MD, N. Hoarau, MD, L. Legros, MD, C. Ravoet, MD, F. Dreyfus, MD, A. Stamatoullas, MD, M.P. Chaury, MD, J. Delaunay, MD, G. Laurent, MD, N. Vey, MD, L. Ades, MD, C. Gardin, MD, Pierre Fenaux, MD

Blood (2007) 110 (11): 820.

https://doi.org/10.1182/blood.V110.11.820.820

Published: 2007

Journal Articles

Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience.

Blood (2006) 108 (11): 522.

https://doi.org/10.1182/blood.V108.11.522.522

Published: 2006

Journal Articles

Sustained Effect of First Line Sequential Therapy with Intensive Consolidation Chemotherapy and Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) after Reduced Intensity Conditioning (RIC) for Patients with Acute Myeloblastic Leukemia (AML) in First Complete Remission (CR1).

Didier Blaise, MD, R. Tabrizi, MD, C. Faucher, MD, Mohamad Mohty, MD, J.O. Bay, MD, J.M. Boiron, MD, G. Marit, MD, S. Furst, MD, A.M. Stoppa, MD, A. Charbonnier, MD, T. Prebet, MD, C. Chabannon, MD, N. Vey

Blood (2006) 108 (11): 3000.

https://doi.org/10.1182/blood.V108.11.3000.3000

Published: 2006

Journal Articles

No Benefit of Adding High-Dose Melphalan (HDM) Suppported by Autologous Stem Cell Transplantation (SCT) over Treatment with Conventional Induction, HD ARAC Consolidation, and Auto SCT (Busulfan + HDM) for Acute Myelogenous Leukemia (AML) under 60: First Results of the Randomized AML 2001 Trial.

B. Lioure, A. Pigneux, C. Recher, F. Witz, T. Lamy, N. Fegueux, C.E. Bulabois, N. Ifrah, I. Luquet, D. Bouscary, N. Vey, M. Delain, J.O. Bay, P. Turlure, Jean-Luc Harousseau

Blood (2006) 108 (11): 608.

https://doi.org/10.1182/blood.V108.11.608.608

Published: 2006

Journal Articles

Is There a Role for ATRA in Combination to EPO in Lower Risk Myelodysplastic Syndrome? Preliminary Results of a Phase II Study.

Blood (2005) 106 (11): 2537.

https://doi.org/10.1182/blood.V106.11.2537.2537

Published: 2005

Journal Articles

Stem Cell Transplantation in 281 Patients over 60 Years in Onco Hematologic Malignancies: A Single Center Experience.

Anne-Marie Stoppa, MD, N. Vey, MD, C. Faucher, MD, R. Bouabdallah, MD, F. Viret, MD, C. Chabannon, MDPhD, P. Ladaique, MD, D. Coso, MD, A. Charbonnier, MDPhD, J.M. Schiano, MD, P. Viens, MD, J.A. Gastaut, MD, D. Maraninchi, MD, D. Blaise, MD

Blood (2004) 104 (11): 5229.

https://doi.org/10.1182/blood.V104.11.5229.5229

Published: 2004

Journal Articles

First Line Therapy with Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Patients with Acute Myeloblastic Leukemia in First Complete Remission.

Didier Blaise, J.M. Boiron, C. Faucher, M. Mohty, J.O. Bay, K. Bilger, G. Marit, V.J. Bardoux, V. Perreau, D. Coso, A.M. Stoppa, J.A. Gastaut, J. Reiffers, D. Maraninchi, N. Vey

Blood (2004) 104 (11): 101.

https://doi.org/10.1182/blood.V104.11.101.101

Published: 2004

Journal Articles

Long Term Infectious Complications Following Reduced Intensity Conditioning (RIC)Allogeneic HLA-Identical Sibling Transplantation (allo-SCT).

A. Etienne, M. Mohty, C. Faucher, M. Ferrando, R. Benramdane, C. Zandotti, L. Collet, N. Vey, A.M. Stoppa, D. Coso, P. Viens, J.A. Gastaut, D. Blaise

Blood (2004) 104 (11): 1234.

https://doi.org/10.1182/blood.V104.11.1234.1234

Published: 2004

Journal Articles

Fludarabine and Busulfan-Based Reduced Intensity Conditioning (RIC) Allogeneic HLA-Identical Transplantation (allo-SCT) with or without Anti-Thymocyte Globulin (ATG): Comparison between Two Prospective Studies in Patients with Myeloid Malignancies.

Mohamad Mohty, R. Martino, C. Faucher, J.A. Perez-Simon, N. Vey, M.D. Caballero, J.A. Gastaut, J. San Miguel, D. Blaise, J. Sierra

Blood (2004) 104 (11): 1241.

https://doi.org/10.1182/blood.V104.11.1241.1241

Published: 2004

NARROW

Lenalidomide (LEN) in INT 2 and High Risk MDS with DEL 5q. Interim Results of a Phase II Trial by the GFM.

Prognostic Factors and Response Duration in 419 MDS Treated with Erythropoietin±GCSF: The GFM Experience.

Sustained Effect of First Line Sequential Therapy with Intensive Consolidation Chemotherapy and Allogeneic Hematopoietic Stem Cell Transplantation (ASCT) after Reduced Intensity Conditioning (RIC) for Patients with Acute Myeloblastic Leukemia (AML) in First Complete Remission (CR1).

No Benefit of Adding High-Dose Melphalan (HDM) Suppported by Autologous Stem Cell Transplantation (SCT) over Treatment with Conventional Induction, HD ARAC Consolidation, and Auto SCT (Busulfan + HDM) for Acute Myelogenous Leukemia (AML) under 60: First Results of the Randomized AML 2001 Trial.

Is There a Role for ATRA in Combination to EPO in Lower Risk Myelodysplastic Syndrome? Preliminary Results of a Phase II Study.

Stem Cell Transplantation in 281 Patients over 60 Years in Onco Hematologic Malignancies: A Single Center Experience.

First Line Therapy with Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Patients with Acute Myeloblastic Leukemia in First Complete Remission.

Long Term Infectious Complications Following Reduced Intensity Conditioning (RIC)Allogeneic HLA-Identical Sibling Transplantation (allo-SCT).

Fludarabine and Busulfan-Based Reduced Intensity Conditioning (RIC) Allogeneic HLA-Identical Transplantation (allo-SCT) with or without Anti-Thymocyte Globulin (ATG): Comparison between Two Prospective Studies in Patients with Myeloid Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only